Source-grounded facts extracted from EKSO BIONICS HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
EKSO BIONICS HOLDINGS, INC. reported the year ended December 31, 2022 results: revenue $12.9 million, net income $15.1 million, EPS $1.16 per basic and diluted share.
“Revenue for the full year ended December 31, 2022 was $12.9 million, compared to $11.2 million for the same period in 2021, an increase of 15%. This increase was comprised of a $2.1 million increase in EksoHealth revenue, partially offset by a $0.4 million decrease in EksoWorks revenue. Gross profit for the full year ended December 31, 2022 was approximately $6.2 million, representing a gross margin of approximately 48%, compared to gross profit of $6.7 million for the same period in 2021, representing a gross margin of 60%. The decline in gross profit was a result of lower gross margins driven by increases in service and supply chain costs, elevated labor costs, and lower average selling prices of device sales due to sales channel mix. Sales and marketing expenses for the full year ended December 31, 2022 were $7.2 million, compared to $7.3 million for the same period in 2021, a decrease of $0.1 million primarily due to improved efficiencies. Research and development expenses for the”
Earnings Releases
EKSO BIONICS HOLDINGS, INC. reported the quarter ended December 31, 2022 results: revenue $3.6 million, net income $3.2 million, EPS $0.24 per basic and diluted share.
“Revenue was $3.6 million for the quarter ended December 31, 2022, compared to $4.1 million for the same period in 2021. Revenue in the fourth quarter of 2022 included approximately $3.5 million in EksoHealth revenue and approximately $0.1 million in EksoWorks revenue. The Company booked a total of 27 EksoHealth devices in the fourth quarter of 2022. Gross profit for the quarter ended December 31, 2022 was $1.7 million, compared to $2.4 million in the same period in 2021, representing a gross margin of approximately 47% in the fourth quarter of 2022, compared to a gross margin for the same period in 2021 of 59%. The decline in gross margin was primarily due to an increase in service and supply chain costs, elevated labor costs, and lower average selling prices of device sales due to sales channel mix. Sales and marketing expenses for the quarter ended December 31, 2022 were $1.9 million, compared to $2.0 million for the same period in 2021. The decrease was primarily due to lower compen”
Scott G. Davis was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“On December 8, 2022, effective immediately, the Board of Directors (the “Board”) of Ekso Bionics Holdings, Inc. (the “Company”) appointed Scott G. Davis to serve as a director of the Company”
M&A Transactions
EKSO BIONICS HOLDINGS, INC. completed an acquisition involving Parker Hannifin Corporation for $10 million (closed 2022-12-05).
“partner to help power new product development. Ekso Bionics acquired all of Parker’s HMC global business assets in the U.S. and Europe for an aggregate purchase price of $10 million. Ekso paid $5 million at closing and delivered a $5 million subordinated, unsecured zero coupon note payable quarterly over four years, commencing December 31, 2023. “We are”
Steven Sherman was appointed as Executive Chair at EKSO BIONICS HOLDINGS, INC..
“Mr. Sherman will continue to serve as Chair of the Board and will begin serving as Executive Chair of the Company.”
Scott G. Davis was appointed as Chief Executive Officer and Principal Executive Officer at EKSO BIONICS HOLDINGS, INC..
“(ii) the Board appointed Scott G. Davis as Chief Executive Officer and Principal Executive Officer of the Company, each effective immediately.”
Steven Sherman resigned as Chief Executive Officer at EKSO BIONICS HOLDINGS, INC..
“On December 4, 2022, in connection with the closing of the Acquisition, (i) Steven Sherman, the Company’s Chief Executive Officer and Chair of the Company’s board of directors (the “Board”), resigned as the Company’s Chief Executive Officer”
Earnings Releases
EKSO BIONICS HOLDINGS, INC. reported nine months ended September 30, 2022 results: revenue $9.4 million, net income $11.9 million, EPS $0.92 per basic and diluted share.
“of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong cash position of $29.2 million as of September 30, 2022 “Our third quarter results reflected”
Earnings Releases
EKSO BIONICS HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $3.3 million, net income $4.3 million, EPS $0.33 per basic and diluted share.
“results for the three months ended September 30, 2022. Recent Highlights and Accomplishments • Record of 33 EksoNR bookings in the third quarter of 2022 • Reported revenue of $3.3 million in the third quarter of 2022, an increase of 9.2% year-over-year • Reported revenue of $9.4 million in the first nine months of 2022, an increase of 30.6% year-over-year • Strong”
Jerome Wong was appointed as Chief Financial Officer at EKSO BIONICS HOLDINGS, INC..
“approved the appointment of Jerome Wong as Chief Financial Officer, Corporate Secretary and Principal Financial Officer, effective immediately.”
Jerome Wong was appointed as Interim Chief Financial Officer at EKSO BIONICS HOLDINGS, INC..
“the Company’s board of directors (the “Board”) approved the appointment of Jerome Wong as Interim Chief Financial Officer, effective upon Mr. Glenn’s departure.”
John F. Glenn resigned as Chief Financial Officer at EKSO BIONICS HOLDINGS, INC..
“John F. Glenn notified Ekso Bionics Holdings, Inc. (the “Company”) of his decision to resign from his position as the Company’s Chief Financial Officer, effective June 17, 2022, in connection with his retention as an employee at another public company.”
William Shaw resigned as Chief Commercial Officer at EKSO BIONICS HOLDINGS, INC..
“William Shaw, the Chief Commercial Officer of Ekso Bionics Holdings, Inc. (the “Company”) notified the Board of Directors (the “Board”) of his intention to resign as Chief Commercial Officer of the Company effective March 11, 2022”
Stanley Stern was appointed as Lead Independent Director at EKSO BIONICS HOLDINGS, INC..
“Board member Stanley Stern has been designated the Board’s lead independent director.”
Steven Sherman was appointed as Chief Executive Officer at EKSO BIONICS HOLDINGS, INC..
“the Company’s Board appointed Steven Sherman, who currently serves as the Chairman of the Board, to become Chief Executive Officer of the Company effective January 22, 2022.”
Jack Peurach resigned as President, Chief Executive Officer and a director at EKSO BIONICS HOLDINGS, INC..
“Jack Peurach, the President, Chief Executive Officer and a director of Ekso Bionics Holdings, Inc. (the “Company”), notified the Company of his intention to resign as an officer and member of the Board of Directors”
Corinna E. Lathan was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“On December 25, 2021, effective immediately, our Board of Directors (the “Board”) approved an increase in the size of the Board to seven people and appointed Corinna E. Lathan, Ph.D. to serve as a director of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.